Daiichi Sankyo’s DS-8201 gets SAKIGAKE designation in Japan for gastric cancer

This article was originally published here

The Japan Ministry of Health, Labour and Welfare (MHLW) has granted SAKIGAKE Designation to Daiichi Sankyo’s investigational HER2-targeting antibody drug conjugate (ADC) DS-8201 for the treatment of HER2-positive advanced gastric or gastroesophageal junction cancer.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply